Targeting STAT3 has been shown to be an effective strategy to reduce the survival of several aggressive cancers that display constitutive Tyr705 STAT3 activation and p53 mutations, including glioblastoma (19) and pancreatic cancers (20, 21). Here, TP53 is linked to familial pancreatic carcinoma.